NASD · Healthcare · Biotechnology · USA
Arrowhead Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Arrowhead Pharmaceuticals creates therapeutic treatments for difficult-to-treat diseases by using RNA interference to suppress genes responsible for disease. The company maintains drug candidates in various clinical trial phases and recently launched REDEMPLO, its first approved medicine, which lowers triglycerides in patients with Familial Chylomicronemia Syndrome. Through partnerships with biotech and pharmaceutical firms, Arrowhead licenses out certain programs while retaining commercial rights to its own pipeline.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Arrowhead Pharmaceuticals Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on ARWR yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.